Thymosin β4 reduces IL-17-producing cells and IL-17 expression, and protects lungs from damage in bleomycin-treated mice.

[1]  S. Cuzzocrea,et al.  Thymosin β4 protects C57BL/6 mice from bleomycin‐induced damage in the lung , 2013, European journal of clinical investigation.

[2]  J. Kolls,et al.  Targeting IL-17 and TH17 cells in chronic inflammation , 2012, Nature Reviews Drug Discovery.

[3]  Ying Sun,et al.  A New Antifibrotic Target of Ac-SDKP: Inhibition of Myofibroblast Differentiation in Rat Lung with Silicosis , 2012, PloS one.

[4]  Hong Liu,et al.  Blocking IL-17A Promotes the Resolution of Pulmonary Inflammation and Fibrosis Via TGF-β1–Dependent and –Independent Mechanisms , 2011, The Journal of Immunology.

[5]  V. A. Folcik,et al.  The distribution of immunomodulatory cells in the lungs of patients with idiopathic pulmonary fibrosis , 2011, Modern Pathology.

[6]  P. Qiu,et al.  Thymosin β4 inhibits TNF‐α‐induced NF‐κB activation, IL‐8 expression, and the sensitizing effects by its partners PINCH‐1 and ILK , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  E. Mazzon,et al.  MEK inhibition suppresses the development of lung fibrosis in the bleomycin model , 2011, Naunyn-Schmiedeberg's Archives of Pharmacology.

[8]  L. Dupont,et al.  Elevated expression of both mRNA and protein levels of IL-17A in sputum of stable Cystic Fibrosis patients , 2010, Respiratory research.

[9]  Ruimin Wang,et al.  New anti-fibrotic mechanisms of n-acetyl-seryl-aspartyl-lysyl-proline in silicon dioxide-induced silicosis. , 2010, Life sciences.

[10]  T. Wynn,et al.  Bleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent , 2010, The Journal of experimental medicine.

[11]  W. Born,et al.  Gammadelta T cells and Th17 cytokines in hypersensitivity pneumonitis and lung fibrosis. , 2009, Translational research : the journal of laboratory and clinical medicine.

[12]  C. Hogaboam,et al.  Murine models of pulmonary fibrosis. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[13]  F. Drago,et al.  Quantitative Evaluation of Interleukin-12 P40 Gene Expression in Peripheral Blood Mononuclear Cells , 2008, Immunological investigations.

[14]  P. Qiu,et al.  Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent , 2007, Clinical ophthalmology.

[15]  P. Qiu,et al.  Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. , 2007, Experimental eye research.

[16]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[17]  M. Caruso,et al.  Interaction between human lung fibroblasts and T-lymphocytes prevents activation of CD4+ cells , 2005, Respiratory research.

[18]  H. Kleinman,et al.  Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. , 2005, Trends in molecular medicine.

[19]  T. Mcclanahan,et al.  IL-23 drives a pathogenic T cell population that induces autoimmune inflammation , 2005, The Journal of experimental medicine.

[20]  A. Hayday,et al.  Anti‐inflammatory effects in the skin of thymosin‐β4 splice‐variants , 2003 .

[21]  Paul J. Friedman,et al.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors , 2002, American journal of respiratory and critical care medicine.

[22]  A. Otto,et al.  beta-Thymosins, small acidic peptides with multiple functions. , 2001, The international journal of biochemistry & cell biology.

[23]  J. Shellito,et al.  Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. , 2001, American journal of respiratory cell and molecular biology.